| COPD patients | 83 |
| Male | 49 |
| Age yrs | 72±9.3 |
| Fatigue experiences | 4.7±1.6 |
| Fatigue impacts | 4.0±1.9 |
| FEV1 % pred | 51±21 |
| GOLD class I | 24 |
| GOLD class II | 10 |
| GOLD class III | 31 |
| GOLD class IV | 18 |
| mMRC | 2.2±1.2 |
| 6MWD m | 388±115 |
| BMI kg·m−2 | 27±5.3 |
| BODE score | 3.5±2.4 |
| HIV-positive patients | 38 |
| Male | 29 |
| Age yrs | 45±5.9 |
| Fatigue experiences | 5.3±1.9 |
| Fatigue impacts | 4.1±2.3 |
| CD4 count cells·mm−3 | 526±33 |
| Colorectal cancer patients | 38 |
| Male | 13 |
| Age yrs | 68±13.2 |
| Fatigue experiences | 4.4±2.0 |
| Fatigue impacts | 3.2±2.1 |
| Duke’s classification of disease extent | |
| A | 4 |
| B | 9 |
| C | 13 |
| Unknown# | 12 |
Data are presented as n or mean±sd. COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1 s; % pred: % predicted; GOLD: Global Initiative for Chronic Obstructive Lung Disease; mMRC: modified Medical Research Council dyspnoea scale; 6MWD: 6-min walk distance; BMI: body mass index; BODE: body mass, level of airflow obstruction, disablement due to dyspnoea, exercise capacity. #: it is known that no patient in the series had a diagnosis of metastatic cancer.